Overview

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Phase II Multicentric Trial Open Label, Multicenter, randomized to evaluate the efficacy of a Maintenance Therapy in First Complete Remission After Induction for Elderly (≥ 60) Fit Patients With Poor Prognosis Acute Myeloid Leukemia (AML). The disease-free survival (DFS) of the patients included in this study will be compared to the ones of the two previously reported groups of patients treated with the same LIA induction therapy
Phase:
Phase 2
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborator:
Celgene Corporation
Treatments:
Azacitidine
Lenalidomide
Thalidomide